OPC-18 + 5-fluorouracil

OPC-18 + 5-fluorouracil is a **combination therapy** consisting of the putative agent **OPC-18** and the cytotoxic chemotherapeutic **5-fluorouracil**. 5-fluorouracil (5-FU) is a well-characterized **antimetabolite** and pyrimidine analog, which inhibits thymidylate synthase, thereby suppressing DNA synthesis in dividing cancer cells[1][3][5][7]. OPC-18 is not an established or widely recognized small molecule, biologic, or supplement in scientific literature; no authoritative mechanism, structure, developer, or disease context is reported in the data provided or in current biomedical databases as of September 2025. The combination, in principle, would be developed to leverage multiple mechanisms or to improve the efficacy and/or dose-limiting toxicity profile of 5-fluorouracil in the treatment of solid tumors. However, insufficient public data exists regarding OPC-18 specifically, its chemical nature, or its effects when combined with 5-fluorouracil. For combinations, the mechanisms and modalities include those of each constituent.

Other names

OPC-18 + 5-FUOPC-18 plus 5-fluorouracilOPC18 plus 5-fluorouracilOPC 18 plus 5-fluorouracil